CNTB Stock Forecast & Price Target

Connect Biopharma Hldgs is viewed positively because rademikibart delivered a differentiated clinical profile in acute respiratory disease, with a 130 mL placebo-adjusted Day 7 FEV1 gain in asthma and, more importantly for COPD, an 81% reduction in treatment failure, an 85% reduction in new moderate/severe exacerbations, and a 100% reduction in hospital/ED returns in Seabreeze STAT COPD. The results are further strengthened by favorable safety, with fewer TEAEs and SAEs than placebo, and by external validation from tozorakimab Phase 3 data showing that COPD biology often favors event-based endpoints over early lung-function changes. With an approximately $70M market cap and potential peak sales modeled at $271M for acute asthma and $190M for acute COPD, the company appears to have meaningful upside if FDA alignment in 4Q26 supports development.

Connect Biopharma Hldgs is viewed negatively because, despite encouraging Seabreeze STAT COPD data, the company still lacks complete clarity on registrational endpoints for asthma and COPD, leaving a meaningful execution and regulatory risk overhang. Its cash position also appears stretched, with runway guidance only through August 2027 and up to $99M in outstanding Simcere milestones, which may not be enough to fund late-stage development without partner support or dilution. While rademikibart showed an 81% reduction in treatment failures and no hospital or ED returns versus 8.6% for placebo, the only numerical FEV1 improvement was not statistically significant, supporting a cautious stance.